Filtered By:
Drug: Methotrexate

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 18937 results found since Jan 2013.

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news

Mandibular and palatal tori exposed by trauma are risk factors for medication-related osteonecrosis of the jaws: a report from the Copenhagen ONJ cohort
ConclusionsHere, we reported a series of 29 cases of MRONJ with related mandibular or palatal tori among 391 consecutive patients in the Copenhagen ONJ Cohort . We documented that 59% of these cases were associated with trauma, and that in some cases, trauma was preventable (e.g., trauma from impression taking and intubation). Dentists as well as anesthesiologists should be aware of the presence of tori in patients on antiresorptive therapy. Surgical treatment was more successful (100%) compared with nonsurgical treatment (40%).
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - December 15, 2019 Category: ENT & OMF Source Type: research

Antirheumatic medications in pregnancy and breastfeeding
Purpose of review As active rheumatic and musculoskeletal disease during pregnancy increases the risk for pregnancy loss, preterm birth, and maternal illness, ongoing management with pregnancy-compatible medications can improve these outcomes. Selecting and taking these medications can be challenging for rheumatologists and patients due to limited knowledge about potential risks and benefits. Recent findings Fortunately, the American College of Rheumatology, American College of Obstetrics and Gynecology, British Rheumatology Society, and the European League Against Rheumatism have each published recommendations to gui...
Source: Current Opinion in Rheumatology - March 28, 2020 Category: Rheumatology Tags: CLINICAL THERAPEUTICS AND HEMATOLOGIC COMPLICATIONS: Edited by W. Joseph McCune Source Type: research

Posterior reversible encephalopathy syndrome and systemic vasculitis: report of six cases.
CONCLUSIONS: Our study indicates that PRES is a rare condition associated with systemic vasculitis; which may be present at the onset vasculitis symptoms. Antihypertensive drugs should be prescribed if blood pressure is elevated. The impact of immunosuppressive therapy remains unclear. PMID: 26412031 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - September 30, 2015 Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research

A161: Novel 3‐Dimensional Explant Method Facilitates the Study of Lymphocyte Populations in the Synovium and Reveals a Large Population of Resident Memory T cells in Rheumatoid Arthritis
Conclusion:The 3‐dimensional explant culturing method is a novel tool, which can be employed to study lymphocytes that are resident in synovium. We confirmed that the T cells isolated through this technique were phenotypically similar to populations of RA synovial lymphocytes previously assessed by immunohistochemistry and tissue digestion. A population of TRM was identified in all synovial samples, suggesting these T cells may be important in the pathogenesis of inflammatory arthritis, though further study of this population is needed.
Source: Arthritis and Rheumatism - March 27, 2014 Category: Rheumatology Authors: Lauren A. Henderson, Sandra L. King, Sarah Ameri, Scott D. Martin, Barry P. Simmons, Peter A. Nigrovic, Robert C. Fuhlbrigge Tags: Poster Breakout Session I: Genetics and Pathogenesis Thursday, April 3, 2014; 4:00–4:30 PM Source Type: research

Rutin attenuates intestinal toxicity induced by Methotrexate linked with anti-oxidative and anti-inflammatory effects
Methotrexate (MTX) is recognized as an anti-metabolite in cancer chemotherapy and is associated with various toxicities assigned to inflammation and oxidative stress. Rutin has been reported to have significan...
Source: BMC Complementary and Alternative Medicine - March 10, 2016 Category: Complementary Medicine Authors: Raju Gautam, Manjari Singh, Swetlana Gautam, Jitendra Kumar Rawat, Shubhini A Saraf and Gaurav Kaithwas Source Type: research

Novel hyaluronic acid–methotrexate conjugate suppresses joint inflammation in the rat knee: efficacy and safety evaluation in two rat arthritis models
Methotrexate (MTX) is one of the most widely used medications to treat rheumatoid arthritis (RA), and recent studies have also suggested the potential benefit of the drug for the treatment of osteoarthritis (O...
Source: Arthritis Research and Therapy - April 1, 2016 Category: Rheumatology Authors: Tatsuya Tamura, Yoshinobu Higuchi, Hidetomo Kitamura, Naoaki Murao, Ryoichi Saitoh, Tadashi Morikawa and Haruhiko Sato Source Type: research

Shock wave-induced ATP release from osteosarcoma U2OS cells promotes cellular uptake and cytotoxicity of methotrexate
Osteosarcoma is the most prevalent primary malignant bone tumor, but treatment is difficult and prognosis remains poor. Recently, large-dose chemotherapy has been shown to improve outcome but this approach can...
Source: Journal of Experimental and Clinical Cancer Research - October 3, 2016 Category: Cancer & Oncology Authors: Baochang Qi, Tiecheng Yu, Chengxue Wang, Tiejun Wang, Jihang Yao, Xiaomeng Zhang, Pengfei Deng, Yongning Xia, Wolfgang G. Junger and Dahui Sun Source Type: research

Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis
Inflammatory arthritis (IA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA), leads to increased cardiovascular disease occurrence probably due to atherosclerosis...
Source: Arthritis Research and Therapy - October 17, 2017 Category: Rheumatology Authors: Gia Deyab, Ingrid Hokstad, Jon Elling Whist, Milada Cvancarova Smastuen, Stefan Agewall, Torstein Lyberg, Nicoletta Ronda, Knut Mikkelsen, Gunnbjorg Hjeltnes and Ivana Hollan Tags: Research article Source Type: research

Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis
Aiming at rapid decrease of disease activity, there has been a trend to start with higher doses of methotrexate (MTX) in patients newly diagnosed with rheumatoid arthritis (RA), both as monotherapy and in comb...
Source: Arthritis Research and Therapy - November 22, 2017 Category: Rheumatology Authors: Sytske Anne Bergstra, Cornelia F. Allaart, Rosaline van den Berg, Arvind Chopra, Nimmisha Govind, Tom W. J. Huizinga and Robert B. M. Landewe Tags: Research article Source Type: research

Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial
The aim was to analyze characteristics that predict remission induction and subsequent loss of remission in patients with moderately active rheumatoid arthritis (RA) who received full-dose combination etanerce...
Source: Arthritis Research and Therapy - January 16, 2018 Category: Rheumatology Authors: Josef S. Smolen, Annette Szumski, Andrew S. Koenig, Thomas V. Jones and Lisa Marshall Tags: Research article Source Type: research

Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients
Sirukumab, a high-affinity human monoclonal antibody that selectively binds to interleukin-6, has demonstrated efficacy in the treatment of rheumatoid arthritis (RA) in global phase 1 and phase 2 studies. The ...
Source: Arthritis Research and Therapy - March 7, 2018 Category: Rheumatology Authors: Tsutomu Takeuchi, Hisashi Yamanaka, Masayoshi Harigai, Ryo Tamamura, Yuichi Kato, Yoshifumi Ukyo, Toshikazu Nakano, Benjamin Hsu and Yoshiya Tanaka Tags: Research article Source Type: research

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
This double-blind, active-controlled, randomized, multinational study evaluated the efficacy, safety, pharmacokinetics (PK), and immunogenicity of PF-06438179/GP1111 (IxifiTM/Zessly ®), an infliximab biosimilar...
Source: Arthritis Research and Therapy - July 27, 2018 Category: Rheumatology Authors: Stanley B. Cohen, Rieke Alten, Hideto Kameda, Tomas Hala, Sebastiao C. Radominski, Muhammad I. Rehman, Ramesh Palaparthy, Karl Schumacher, Susanne Schmitt, Steven Y. Hua, Claudia Ianos and K. Lea Sewell Tags: Research article Source Type: research

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
Sarilumab is a human immunoglobulin G1 anti-interleukin-6 (IL-6) receptor monoclonal antibody that blocks IL-6 from binding to membrane-bound and soluble IL-6 receptor α. This bridging study assessed the effic...
Source: Arthritis Research and Therapy - March 20, 2019 Category: Rheumatology Authors: Yoshiya Tanaka, Kazuteru Wada, Yoshinori Takahashi, Owen Hagino, Hubert van Hoogstraten, Neil M. H. Graham and Hideto Kameda Tags: Research Source Type: research

Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
To address whether the use of methotrexate (MTX) and biological disease-modifying anti-rheumatic drugs (bDMARDs) impacts bone structure and biomechanical properties in patients with psoriatic arthritis (PsA).
Source: Arthritis Research and Therapy - July 3, 2019 Category: Rheumatology Authors: David Simon, Arnd Kleyer, Sara Bayat, Koray Tascilar, Eleni Kampylafka, Timo Meinderink, Louis Schuster, Ramona Petrov, Anna-Maria Liphardt, Juergen Rech, Georg Schett and Axel J. Hueber Tags: Research article Source Type: research